Aging and Longevity Claims
A claim check on peptides marketed for anti-aging and longevity, covering epitalon, growth-hormone-releasing peptides and mitochondrial peptides, and why a biomarker change is not slower aging.
Content last updated . This page has not been medically reviewed.
Evidence labels used here. Preclinical: cells or animals only. Insufficient evidence: too little human data to judge. Promising but limited: some human data, small or indirect. Mixed: studies disagree. Marketing claim: a statement made to sell, without supporting trials. Proper evidence not found: we looked and found nothing usable. A biomarker is a measurement such as telomere length, blood IGF-1 or a hormone level. A clinical outcome is living longer, staying independent or avoiding disease. A higher or lower biomarker is not inherently better.
For well-supported ways to age well, see Longevity Interventions: What Human Evidence Exists, Healthy Aging and Claim Check: "Peptides Reverse Aging".
What reviewers say overall
A 2026 narrative review of peptides discussed in healthy aging (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin and bremelanotide) selected 20 primary sources. [1] It concluded that non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. [1] The same review noted that FDA-approved agents had robust safety profiles from large trials, which the non-approved ones lack. [1] Approved and unapproved compounds sit side by side in such reviews, but they are very different things.Epitalon
Identity. Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) developed from the amino-acid composition of epithalamin, which is a different, pineal-derived preparation. [2] The two names are not interchangeable.| Evidence | Model and design | Result | Limits |
|---|---|---|---|
| Cell study (2025) | Human breast cancer cell lines and normal epithelial and fibroblast cells treated with epitalon [3] | Telomeres lengthened in normal cells through telomerase activity; in cancer cells they lengthened through a different route (ALT) [3] | Preclinical. A correction notice was later published for this paper. [4] Longer telomeres in a dish are not slower aging in a person. |
| Thymalin and epithalamin follow-up (2003) | 266 elderly people followed 6 to 8 years; the peptide preparations were given in the first 2 to 3 years [5] | The authors reported lower death rates and fewer illnesses than controls [5] | These were thymic and pineal preparations, not epitalon. [5] The abstract does not describe randomization, blinding or a placebo, and the work was reported by the two institutes that ran it, with no independent replication found in the sources checked. |
| Human evidence overall (2026 review) | Narrative review of mechanistic, preclinical and human studies [2] | Human evidence limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa [2] | No adequately powered randomized trial has established therapeutic efficacy, and dose-finding and long-term safety data remain inadequate. [2] |
Evidence label: preclinical for aging claims, with insufficient evidence in people. The review called epitalon "biologically active but clinically unproven". [2]
Growth-hormone-releasing peptides
Marketing often says that raising growth hormone (GH) or IGF-1 reverses aging. Two sources checked show why that is not established.- Tesamorelin trial (2012). A randomized, double-blind, placebo-controlled trial gave tesamorelin, a stabilized analog of GH-releasing hormone, to 152 adults aged 55 to 87 (66 with mild cognitive impairment) for 20 weeks. [6] IGF-1 rose 117% and a cognitive test composite improved modestly (p = 0.03). [6] Adverse events were reported in 68% of treated adults versus 36% on placebo. [6] This measured thinking tests, not lifespan or disease. Funder not stated in the abstract read.
- Growth hormone itself in healthy older people (2007 review). A systematic review of 18 study populations found small changes in body composition and higher rates of adverse events, including swelling, joint pain, carpal tunnel syndrome and gynecomastia (breast tissue growth). [7] Most studies were small. [7] The review also stated that, at that time, FDA had not approved growth hormone for anti-aging use. [7]
More on this family is on Growth-Hormone-Releasing Peptides and Peptides vs Growth Hormone.
Mitochondrial and other "longevity" peptides
MOTS-c and humanin are described mainly in rodent and cell work, with human data limited to circulating levels. [8] See Mitochondrial Disorders. Evidence label: preclinical.How to judge an anti-aging peptide claim
Ask: Which exact molecule? Which people were studied, how many, for how long? Was there a placebo? Did the study measure staying healthy, or only a marker? Who paid? Is there independent replication? See How to Evaluate Peptide Claims and Clinic Marketing.Frequently asked questions
Do peptides slow aging?
Proper evidence not found in human trials in the sources checked. Evidence is preclinical or biomarker-based. [1][2]
Does epitalon lengthen telomeres in people?
A 2025 cell study found longer telomeres in cultured cells, including cancer cells. Human trials showing this lead to slower aging were not found. [3][2]
Is higher IGF-1 a sign of anti-aging?
No. In one trial IGF-1 rose 117% and test scores improved modestly, but disease or lifespan were not measured. [6]
Did the Russian studies prove peptide bioregulators extend life?
A 2003 report described lower death rates after thymic and pineal preparations, but not epitalon, and the abstract gives no placebo or blinding details. [5]
Are approved peptide medicines anti-aging treatments?
No. Approved peptide medicines are approved for named conditions, and none of the medicine labels read for this group of pages names aging as an indication.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Regulatory note (United States)
References
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging 2026. PubMed abstract read 2026-10-22.
- Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci 2026. PubMed abstract read 2026-10-22.
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025. PubMed abstract read 2026-10-22.
- Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025. PubMed abstract read 2026-10-22.
- Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003. PubMed abstract read 2026-10-22.
- Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 2012. PubMed abstract read 2026-10-22.
- Liu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007. PubMed abstract read 2026-10-22.
- Mitochondrial-derived peptides in energy metabolism. Am J Physiol Endocrinol Metab 2020. PubMed abstract read 2026-10-22.
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page content current as of 04/22/2026). Read 2026-10-22.